

**Section: Demographics**
**Parent: Root**

<b>Element:</b> 2000	Last Name
	<p><b>Coding Instruction:</b> Indicate the patient's last name. Hyphenated names should be recorded with a hyphen.</p> <p><b>Target Value:</b> The value on arrival at this facility</p>
<b>Element:</b> 2010	First Name
	<p><b>Coding Instruction:</b> Indicate the patient's first name.</p> <p><b>Target Value:</b> The value on arrival at this facility</p>
<b>Element:</b> 2020	Middle Name
	<p><b>Coding Instruction:</b> Indicate the patient's middle name.</p> <p>Note(s): It is acceptable to specify the middle initial.</p> <p>If there is no middle name given, leave field blank.</p> <p>If there are multiple middle names, enter all of the middle names sequentially.</p> <p>If the name exceeds 50 characters, enter the first 50 letters only.</p> <p><b>Target Value:</b> The value on arrival at this facility</p>
<b>Element:</b> 2050	Birth Date
	<p><b>Coding Instruction:</b> Indicate the patient's date of birth.</p> <p><b>Target Value:</b> The value on arrival at this facility</p> <p><b>Vendor Instruction:</b> Date Rule 1: Date of Birth(2050) is greater than 01/01/1850 (DOB &gt; 1/1/1850) Date Rule 2: Date of Birth(2050) is less than Arrival Date and Time(3001) (DOB &lt; ArrivalDateTime) Date Rule 3: Patient must be 18 years or older to be included in the Auxiliary Data Collection Tool (ArrivalDateTime - DOB &gt;= 18 years)</p>
<b>Element:</b> 2040	Patient ID
	<p><b>Coding Instruction:</b> Indicate the number created and automatically inserted by the software that uniquely identifies this patient.</p> <p>Note(s): Once assigned to a patient at the participating facility, this number will never be changed or reassigned to a different patient. If the patient returns to the same participating facility or for follow up, they will receive this same unique patient identifier.</p> <p><b>Target Value:</b> The value on arrival at this facility</p>
<b>Element:</b> 2045	Other ID
	<p><b>Coding Instruction:</b> Indicate an optional patient identifier, such as medical record number, that can be associated with the patient.</p> <p><b>Target Value:</b> N/A</p>

**Section: Episode of Care** **Parent: Root**

**Element:** 2999 **Episode Unique Key**

**Coding Instruction:** Indicate the unique key associated with each patient episode record as assigned by the EMR/EHR or your software application.  
**Target Value:** N/A

**Element:** 3001 **Arrival Date and Time**

**Coding Instruction:** Indicate the date and time the patient arrived at your facility.  
 Note(s):  
 Indicate the time (hours:minutes) using the military 24-hour clock, beginning at midnight (00:00 hours).  
**Target Value:** N/A

**Element:** 10101 **Discharge Date and Time**

**Coding Instruction:** Indicate the date and time the patient was discharged from your facility as identified in the medical record.  
 Note(s):  
 Indicate the time (hours:minutes) using the military 24-hour clock, beginning at midnight (00:00 hours).  
 If the exact discharge time is not specified in the medical record, then code the appropriate time as below.  
 0000 - 0559 (midnight to before 6AM) code 0300  
 0600 - 1159 (6AM - before noon) code 0900  
 1200 - 1759 (noon before 6PM) code 1500  
 1800 - 2359 (6PM to before midnight) code 2100  
**Target Value:** The value on discharge

**Element:** 14627 **DCT Unique Patient Identifier**

**Coding Instruction:** Indicate the data collection tool (DCT) unique patient identifier.  
 Note(s):  
 If you entered the base record using the ACC's NCDR data collection tool, the DCT unique patient identifier is identical to that NCDR patient ID and can be found in the left menu of the Auxiliary data collection tool.  
 If you entered the base record using a Vendor data collection tool, retrieve the NCDR unique patient identifier generated by your vendor software and enter it in this field (it will not match the NCDR patient ID created by the Auxiliary data collection tool).  
 Because the DCT unique patient identifier is created by the registry specific data collection tool, the base record must be entered first prior to entering the patient in the Auxiliary data collection tool.  
**Target Value:** N/A

**Element:** 14599 **COVID-19 Status**

**Coding Instruction:** Indicate the patient's COVID-19 status.  
**Target Value:** The highest value on arrival or prior to discharge

**COVID-19 Status - 1.3.6.1.4.1.19376.1.4.1.6.5.751**

Selection	Definition	Source	Code	Code System
COVID-19 Data Not Collected	The facility is not participating in the collection of COVID-19 data.		112000002082	ACC NCDR
COVID-19 Positive	The patient has tested positive for COVID-19.		112000001982	ACC NCDR
COVID-19 Suspected	Testing for COVID-19 was either not performed OR was negative; however, due to the presence of clinical signs/symptoms consistent with COVID-19 there was a high level of suspicion the infection was present which guided the overall treatment plan.	ACC NCDR	840544004	SNOMED CT
COVID-19 Recovered	The patient was previously diagnosed with COVID-19 infection (lab or clinical criteria) and is no longer contagious as defined by:  Test-based strategy: At least three (3) days (72 hours) have passed since recovery which is defined as the resolution of fever and improvement of respiratory symptoms, AND Two (2) consecutive negative COVID-19 laboratory tests >= 24 hours apart	"Discontinuation of Isolation for Persons with COVID - 19 Not in Healthcare Settings Interim Guidance," retrieved from: <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html</a>	112000001984	ACC NCDR

**Section: Episode of Care** **Parent: Root**

OR

Symptom-based strategy:  
 At least three (3) days (72 hours) have passed since recovery which is defined as the resolution of fever and improvement of respiratory symptoms, AND  
 At least ten (10) days have passed since symptom onset

OR

If tested positive for COVID-19 and never exhibited symptoms:  
 At least 10 days have passed since first positive COVID-19 test, OR  
 Two (2) consecutive negative COVID-19 laboratory tests  $\geq$  24 hours apart

COVID-19 Negative	The patient has tested negative for COVID-19.	11200001983	ACC NCDR
COVID-19 Testing Not Performed	The patient has not been tested for COVID-19.	11200001985	ACC NCDR
Other	The patient has a COVID-19 status that is not available for selection.	100000351	ACC NCDR

**Section: Labs** **Parent: COVID-19 Hospital Course**

**Element:** 14600                      Troponin Type

---

**Coding Instruction:** Indicate the type of troponin test performed.

Note(s):  
If both Troponin I and T were obtained, only report the type with the highest numerical value.

Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Troponin Type - 1.3.6.1.4.1.19376.1.4.1.6.5.758**

Selection	Definition	Source	Code	Code System
Troponin I			10839-9	LOINC
Troponin T			6598-7	LOINC

**Element:** 14601                      Troponin Not Drawn

---

**Coding Instruction:** Indicate if the troponin was not drawn.

**Target Value:** N/A

**Element:** 14602                      Troponin Test Location

---

**Coding Instruction:** Indicate if the troponin blood sample was run at the point of care (POC) or in the laboratory.

**Target Value:** The value on arrival or prior to discharge

**Troponin Test Location**

Selection	Definition	Source	Code	Code System
Lab			112000000387	ACC NCDR
POC			112000000388	ACC NCDR

**Element:** 14603                      Lab Troponin Assay and URL

---

**Coding Instruction:** Indicate the assay used for the troponin sample that was processed in the lab.

**Target Value:** The value on arrival or prior to discharge

**Element:** 14604                      Point of Care Troponin Assay and URL

---

**Coding Instruction:** Indicate the assay used for the troponin sample that was processed at the point of care.

**Target Value:** The value on arrival or prior to discharge

**Element:** 14605                      Troponin

---

**Coding Instruction:** Indicate the Troponin value.

Note(s):  
Labs obtained at a previous facility are permissible.

If the value is reported using a "<" symbol (e.g., <0.02), record the number only (e.g., 0.02).

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14607                      Brain Natriuretic Peptide

---

**Coding Instruction:** Indicate the brain natriuretic peptide (BNP) value.

Note(s):  
Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14608                      Brain Natriuretic Peptide Not Drawn

---

**Coding Instruction:** Indicate if the brain natriuretic peptide (BNP) was not drawn.

**Target Value:** N/A

**Element:** 14611                      N-Terminal Pro B-type Natriuretic Peptide

---

**Coding Instruction:** Indicate the N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) value.

## Section: Labs

## Parent: COVID-19 Hospital Course

Note(s):  
Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14612 N-Terminal Pro B-type Natriuretic Peptide Not Drawn

**Coding Instruction:** Indicate if the N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) was not drawn.

**Target Value:** N/A

**Element:** 14609 C-Reactive Protein

**Coding Instruction:** Indicate the C-reactive protein (CRP) value.

Note(s):  
Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14610 C-Reactive Protein Not Drawn

**Coding Instruction:** Indicate if the C-reactive protein (CRP) was not drawn.

**Target Value:** N/A

**Element:** 14613 D-Dimer

**Coding Instruction:** Indicate the D-Dimer value.

Note(s):  
Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14615 D-Dimer Not Drawn

**Coding Instruction:** Indicate if the D-Dimer was not drawn.

**Target Value:** N/A

**Element:** 14619 Lactate Dehydrogenase

**Coding Instruction:** Indicate the lactate dehydrogenase (LDH) value.

Note(s):  
Labs obtained at a previous facility are permissible.

**Target Value:** The highest value on arrival or prior to discharge

**Element:** 14620 Lactate Dehydrogenase Not Drawn

**Coding Instruction:** Indicate if the lactate dehydrogenase (LDH) was not drawn.

**Target Value:** N/A

**Section: Hospital Course** **Parent: COVID-19 Hospital Course**

**Element:** 14616 COVID-19 Therapies

**Coding Instruction:** Indicate the COVID-19 therapies that were administered.

Note(s): If the patient was enrolled in a clinical trial and therapies were blinded, select "clinical drug/treatment trial" and enter the clinical trial information in the subsequent fields.

**Target Value:** Any occurrence between arrival and discharge

**Vendor Instruction:** Rule 1: If 'Clinical Drug or Treatment Trial' is selected under COVID-19 Therapies (14616), Patient Enrolled in Clinical Trial (14622) must be selected as Yes.

**COVID-19 Therapies - 1.3.6.1.4.1.19376.1.4.1.6.5.757**

Selection	Definition	Source	Code	Code System
Aviptadil			423560002	SNOMED CT
Azithromycin			18631	RxNorm
Bamlanivimab			2463114	RxNorm
Baricitinib			2047232	RxNorm
Bebtelovimab			2592360	RxNorm
Bevacizumab			253337	RxNorm
Casirivimab / Imdevimab			2557234	RxNorm
Chloroquine			2393	RxNorm
Convalescent Plasma			11200001989	ACC NCDR
Dexamethasone			3264	RxNorm
Eculizumab			591781	RxNorm
Etesevimab			2477854	RxNorm
Famotidine			4278	RxNorm
Fibrinolysis			385538006	SNOMED CT
Fingolimod			1012892	RxNorm
Hydroxychloroquine			5521	RxNorm
Interferon			11200001993	ACC NCDR
Intravenous Corticosteroids			11200001994	ACC NCDR
Intravenous Immunoglobulin			42386	RxNorm
Pirfenidone			1592254	RxNorm
Remdesivir			2284718	RxNorm
Sarilumab			1923319	RxNorm
Tocilizumab			612865	RxNorm
Vitamin C			1151	RxNorm
Clinical Drug or Treatment Trial			185922005	SNOMED CT

**Element:** 14621 COVID-19 Therapies None Administered

**Coding Instruction:** Indicate if none of the listed COVID-19 therapies were administered during the episode of care.

**Target Value:** N/A

**Element:** 14622 Patient Enrolled in Clinical Trial

**Coding Instruction:** Indicate if the patient is enrolled in a clinical trial specific to the treatment of COVID-19.

**Target Value:** Any occurrence between arrival and discharge

**Element:** 14617 Events During Hospitalization

**Coding Instruction:** Indicate the event(s) that occurred.

Note(s):  
If the event was previously documented in the base dataset, also document it in this event list.

**Target Value:** Any occurrence between arrival and discharge

**Events During Hospitalization - 1.3.6.1.4.1.19376.1.4.1.6.5.755**

Selection	Definition	Source	Code	Code System
Atrial Fibrillation	Atrial Fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activity with consequent deterioration of atrial mechanical function. On the electrocardiogram (ECG), atrial fibrillation is characterized by the replacement of consistent P waves with rapid oscillations or fibrillation waves that vary in amplitude, shape and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact.	ACC/AHA 2006 Data Standards for Measuring Clinical Management and Outcomes of Patients with Atrial Fibrillation	49436004	SNOMED CT

Section: Hospital Course		Parent: COVID-19 Hospital Course		
Invasive Mechanical Ventilation	Invasive ventilation is the administration of ventilatory support with utilization of an artificial airway such as an endotracheal tube or tracheostomy.		11200001990	ACC NCDR
Ventricular Fibrillation	Fibrillation is an uncontrolled twitching or quivering of muscle fibers occurring in the lower chambers of the heart (ventricles).	JACC Vol. 48, No. 11, 2006 ACC/AHA/HRS Clinical Data Standards December 5, 2006:2360-96	71908006	SNOMED CT
Noninvasive Positive Pressure Ventilation	Noninvasive positive pressure ventilation is the administration of ventilatory support without utilizing an artificial airway such as an endotracheal tube or tracheostomy.  Note(s): This includes any of the following devices with ventilation delivered nasally, via mask or helmet: 1. Bilevel positive airway pressure (BiPAP) 2. Continuous positive airway pressure (CPAP) 3. Other non-invasive positive pressure devices	Jones LD, Park JG. Noninvasive positive pressure ventilation. Hosp Med Clin;3:(2014), e149-e161.	447837008	SNOMED CT
Ventricular Tachycardia	Ventricular tachycardia (VT) that is > 30 seconds in duration and/or requires termination due to hemodynamic compromise in < 30 seconds.		25569003	SNOMED CT
Venovenous Extracorporeal Membrane Oxygenation	Venovenous extracorporeal membrane oxygenation (VV ECMO) is a system that drains blood from a large central vein and pumps it through a gas-exchange device that oxygenates the blood while removing carbon dioxide before returning it through a large central vein.  Note(s): ECMO utilized to provide ventricular support is not captured here (e.g. VA ECMO)	Fan E, Del Sorbo L, Goligh EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adults with Acute Respiratory Distress Syndrome. Am J Resp Crit Care Med;195:9, 1253-1263.	786453001	SNOMED CT
Heart Failure	Heart failure is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The cardinal manifestations of HF are dyspnea and fatigue, which may limit exercise tolerance, and fluid retention, which may lead to pulmonary and/or splanchnic congestion and/or peripheral edema. Some patients have exercise intolerance but little evidence of fluid retention, whereas others complain primarily of edema, dyspnea, or fatigue. Because some patients present without signs or symptoms of volume overload, the term "heart failure" is preferred over "congestive heart failure." There is no single diagnostic test for HF because it is largely a clinical diagnosis based on a careful history and physical examination.	2013 ACCF/AHA Guideline for the Management of Heart Failure; J Am Coll Cardiol. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019	84114007	SNOMED CT
Renal Replacement Therapy	Renal replacement therapy includes any of the following: 1. Hemodialysis 2. Peritoneal Dialysis 3. Continuous Venovenous Hemofiltration 4. Continuous Venovenous Hemodialysis		265764009	SNOMED CT
Myocarditis	Myocarditis is an inflammatory disease of the myocardium resulting from viral infections and/or post-viral immune-mediated responses.	Kindermann I, Barth C, Mahfoud F, et al. Update on Myocarditis. J Am Coll Cardiol 2012;59:779-792.	50920009	SNOMED CT
Stroke - Embolic	An embolic stroke is an acute episode of focal or global neurological dysfunction caused by a blood clot which formed elsewhere in the body and traveled in the bloodstream to the brain.		371041009	SNOMED CT
Pericarditis	Pericarditis is the inflammation of the pericardial layers characterized by chest pain, electrocardiographic changes and often pericardial effusion. It is often the result of an infectious or a noninfectious process but can also be idiopathic.	Chiabrando JG, Bonaventure A, Vecchie A, et al. Management of acute and recurrent pericarditis. J Am Coll Cardiol 2020;75:76-92.	3238004	SNOMED CT
Stroke - Hemorrhagic	Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke.  Hemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.  Note: Subdural hematomas are intracranial hemorrhagic events and not strokes.	Hicks KA, Tchong JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66(4):403-469. doi:10.1016/j.jacc.2014.12.018.	230706003	SNOMED CT
Intravenous Inotrope(s)	Inotropic agents increase myocardial contractility. Any of the following medications are considered inotropes:		11200001987	ACC NCDR

Section: Hospital Course		Parent: COVID-19 Hospital Course	
	Amrinone Dobutamine Inamrinone Milrinone		
Stroke - Ischemic	An ischemic stroke is an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of infarction of central nervous system tissue.	422504002	SNOMED CT
Intravenous Vasopressor(s)	Vasopressor agents cause vasoconstriction. Any of the following medications are considered vasopressors: Dopamine Epinephrine Norepinephrine Phenylephrine Vasopressin	112000001988	ACC NCDR
Stroke - Undetermined	A stroke of undetermined origin is defined as an acute episode of focal or global neurological dysfunction caused by presumed brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction but with insufficient information to allow categorization as ischemic or hemorrhagic.	230713003	SNOMED CT
Mechanical Ventricular Support		100014009	ACC NCDR
Deep Venous Thrombosis	Deep vein thrombosis (DVT) refers to the formation of one or more blood clots (a blood clot is also known as a 'thrombus,' while multiple clots are called 'thrombi') in one of the body's large veins, most commonly in the lower limbs (e.g., lower leg or calf)	Office of the Surgeon General. (2008). The surgeon general's call to action to prevent deep vein thrombosis and pulmonary embolism. Retrieved from <a href="https://www.ncbi.nlm.nih.gov/books/NBK44184/">https://www.ncbi.nlm.nih.gov/books/NBK44184/</a>	128053003 SNOMED CT
Pneumonia		233604007	SNOMED CT
Disseminated Intravascular Coagulation	A syndrome caused by an underlying disease process which leads to the activation of coagulation resulting in bleeding/hemorrhage and intravascular thrombosis.	Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Path; 146:6, 670-680.	67406007 SNOMED CT
Acute Respiratory Distress Syndrome	Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure characterized by inflammatory edema resulting in severe hypoxemia.	Fan E, Del Sorbo L, Goligh EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adults with Acute Respiratory Distress Syndrome. Am J Resp Crit Care Med;195:9, 1253-1263.	67782005 SNOMED CT
Pulmonary Embolus	Intravascular migration of a venous thrombus to the pulmonary arterial circulation. A 'Proved Pulmonary Embolism' is proved by a positive pulmonary angiogram, an unequivocally positive helical CT scan, a high-probability ventilation-perfusion scan, or autopsy.	Banovac, F., et al. Reporting Standards for Endovascular Treatment of Pulmonary Embolism. Journal of Vascular Interventional Radiology 2010; 21:44-53	59282003 SNOMED CT
High-Flow Nasal Cannula Oxygen	Unlike the traditional nasal cannula, high-flow nasal cannula oxygen therapy (HFNC) can deliver flow rates as high as 60 liters/minute. The therapy is delivered through a system that includes: an air/oxygen blender, heated humidifier, and nasal cannula.	Lee C, Mankodi D, Shaharyar S, et al. High-flow nasal cannula versus conventional oxygen therapy and non-invasive ventilation in adults with acute hypoxemic respiratory failure: A systematic review. Respiratory Medicine. 2016;121: 100-108.  Nishimura M. High-flow nasal cannula oxygen therapy in adults: Physiological benefits, indication, clinical benefits, and adverse effects. Respir Care. 2016; 61 (4):529-41.	112000002052 ACC NCDR
Other Thrombotic Event	A thrombotic event occurred that is not available for selection.		112000001991 ACC NCDR

**Element: 14618** Events During Hospitalization None Documented

**Coding Instruction:** Indicate if none of the listed events occurred during the episode of care.  
**Target Value:** N/A

**Element: 14625** Number of Days Mechanically Ventilated

**Coding Instruction:** Indicate the total number of days the patient was mechanically ventilated.  
**Note(s):**  
 Count each calendar day the patient received invasive mechanical ventilation; the day ventilation was initiated is day 1.  
 The total number of days includes invasive mechanical ventilation delivered through either an endotracheal tube or tracheostomy.  
**Target Value:** The value between arrival at this facility and discharge

**Element: 14626** Mechanical Ventricular Support Device(s)



**Section: Hospital Course**
**Parent: COVID-19 Hospital Course**

**Coding Instruction:** Indicate all mechanical ventricular support devices used.

Note(s): The device that should be collected in your application are controlled by a Mechanical Ventricular Support Master file. This file is maintained by the NCDR and will be made available on the internet for downloading and importing/updating into your application.

**Target Value:** All values between arrival at this facility and discharge

**Vendor Instruction:** Rule 1: For each Episode of Care, Mechanical Ventricular Support Devices (14626) must be unique, no duplicate devices.

**Mechanical Ventricular Support Device - 2.16.840.1.113883.3.3478.6.1.24**

Selection	Definition	Source	Code	Code System
Cardiopulmonary Support (CPS)			1000142428	ACC NCDR
Extracorporeal membrane oxygenation (ECMO)			233573008	SNOMED CT
Impella: Left Ventricular Support			100014011	ACC NCDR
Impella: Right Ventricular Support			112000000188	ACC NCDR
Intra-aortic balloon pump (IABP)			442807006	SNOMED CT
Left ventricular assist device (LVAD)			232967006	SNOMED CT
Right Ventricular Assist Device (RVAD)			360065002	SNOMED CT
Percutaneous Heart Pump (PHP)			1000142429	ACC NCDR
TandemHeart			100014010	ACC NCDR
Biventricular Axial Flow Impella Catheters (BiPella)			112000001980	ACC NCDR
Combined Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Assist Device (EPELLA)			112000002051	ACC NCDR

**Section: Clinical Trial**
**Parent: Hospital Course**
**Element:** 14628                      COVID-19 Clinical Trial Identification

**Coding Instruction:** Indicate the clinical trial name and the national clinical trial number (NCT) for each study the patient was enrolled in.

Note(s): The clinical trial(s) collected in this field are obtained from the clinicaltrials.gov website and controlled by the COVID-19 Clinical Trials Master file. This file is maintained by the NCDR and will be made available on the internet for downloading and importing/updating into your application.

**Target Value:** N/A

**Vendor Instruction:** Rule 1: For each Episode of Care, COVID-19 Clinical Trial Identification (14628) must be unique, no duplicate clinical trials.

**COVID-19 Clinical Trial - 1.3.6.1.4.1.19376.1.4.1.6.5.759**

Selection	Definition	Source	Code	Code System
NCT04400032 - Cellular Immuno-Therapy for COVID ARDS			NCT04400032	clinicaltrials.gov
NCT04391309 - CaTT Covid Trial			NCT04391309	clinicaltrials.gov
NCT05210101 - Sotrovimab prophylaxis in immunocompromised individuals			NCT05210101	clinicaltrials.gov
Other COVID-19 Clinical Trial			11200001998	ACC NCDR
NCT03648372 - TAK-981 in Metastatic Tumors or Malignancies			NCT03648372	clinicaltrials.gov
NCT03808922 - DAS181 Lower Tract PIV in Immunocompromised			NCT03808922	clinicaltrials.gov
NCT03852537 - Steroid Dosing Guided Titration in Pneumonia			NCT03852537	clinicaltrials.gov
NCT04278404 - Understudied Drugs Administered to Children			NCT04278404	clinicaltrials.gov
NCT04280705 - Adaptive COVID-19 Treatment Trial			NCT04280705	clinicaltrials.gov
NCT04283461 - Vaccine (mRNA-1273) for Prophylaxis of COVID			NCT04283461	clinicaltrials.gov
NCT04292730 - Remdesivir in Moderate COVID			NCT04292730	clinicaltrials.gov
NCT04292899 - Remdesivir in Severe COVID			NCT04292899	clinicaltrials.gov
NCT04305457 - Nitric Oxide Gas for Mild/Moderate COVID			NCT04305457	clinicaltrials.gov
NCT04306393 - Nitric Oxide in Severe Acute Respiratory Syndrome			NCT04306393	clinicaltrials.gov
NCT04308668 - Post-exposure Prophylaxis / Preemptive Therapy			NCT04308668	clinicaltrials.gov
NCT04311177 - Losartan for Patient Not Requiring Hospitalization			NCT04311177	clinicaltrials.gov
NCT04311697 - IV Aviptadil for Acute Respiratory Distress			NCT04311697	clinicaltrials.gov
NCT04312009 - Losartan for Patients Requiring Hospitalization			NCT04312009	clinicaltrials.gov
NCT04312997 - PUL-042 Inhalation to Reduce Severity of COVID			NCT04312997	clinicaltrials.gov
NCT04313023 - PUL-042 in Adults Exposed to SARS-CoV-2			NCT04313023	clinicaltrials.gov
NCT04315298 - Sarilumab in Hospitalized Patients With COVID			NCT04315298	clinicaltrials.gov
NCT04317040 - CD24Fc as a Non-antiviral Immunomodulator			NCT04317040	clinicaltrials.gov
NCT04318444 - Hydroxychloroquine Post Exposure Prophylaxis			NCT04318444	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
NCT04319445 - Mindfulness During COVID-19	NCT04319445		clinicaltrials.gov
NCT04319731 - Human Amniotic Fluid for Respiratory Failure	NCT04319731		clinicaltrials.gov
NCT04320472 - Acute Encephalopathy in Critically Ill COVID	NCT04320472		clinicaltrials.gov
NCT04320511 - Beaumont Quantitative Lung Function Imaging	NCT04320511		clinicaltrials.gov
NCT04320615 - Tocilizumab in Severe COVID Pneumonia	NCT04320615		clinicaltrials.gov
NCT04320862 - COVID-19 Pandemic Response Network	NCT04320862		clinicaltrials.gov
NCT04321369 - Impact of Swab Site and Collector on Sensitivity	NCT04321369		clinicaltrials.gov
NCT04321811 - Behavior, Environment And Treatments for Covid-19	NCT04321811		clinicaltrials.gov
NCT04322682 - Colchicine Coronavirus SARS-CoV2 Trial	NCT04322682		clinicaltrials.gov
NCT04323761 - Remdesivir for the Treatment of COVID-19	NCT04323761		clinicaltrials.gov
NCT04323787 - Viral Infection and Respiratory Illness Study	NCT04323787		clinicaltrials.gov
NCT04323839 - Pregnancy CoRonavirus Outcomes ReglsTrY	NCT04323839		clinicaltrials.gov
NCT04325906 - Early PP With HFNC in COVID Induced ARDS	NCT04325906		clinicaltrials.gov
NCT04326036 - cSVF Via IV for Residual Lung Damage	NCT04326036		clinicaltrials.gov
NCT04326309 - Audio Data Collection Classification of Coughing	NCT04326309		clinicaltrials.gov
NCT04326426 - Tradipitant in Severe or Critical COVID	NCT04326426		clinicaltrials.gov
NCT04326452 - Treating With Bidirectional Oxygenation Valve	NCT04326452		clinicaltrials.gov
NCT04327804 - Longitudinal Study of COVID Nasal Swabs and Blood	NCT04327804		clinicaltrials.gov
NCT04328012 - Comparison Of Therapeutics for Patients	NCT04328012		clinicaltrials.gov
NCT04328467 - Pre-exposure Prophylaxis for SARS-Coronavirus-2	NCT04328467		clinicaltrials.gov
NCT04328961 - Hydroxychloroquine for COVID -19 PEP	NCT04328961		clinicaltrials.gov
NCT04329533 - Mobile App on Perceived Stress	NCT04329533		clinicaltrials.gov
NCT04329832 - Hydroxychloroquine vs. Azithromycin for COVID-19	NCT04329832		clinicaltrials.gov
NCT04329897 - Acceptance and Commitment Therapy by Software	NCT04329897		clinicaltrials.gov
NCT04329923 - Prevention And Treatment With Hydroxychloroquine	NCT04329923		clinicaltrials.gov
NCT04331366 - Bidirectional O2 Valve in Pulmonary Complications	NCT04331366		clinicaltrials.gov
NCT04331509 - COVID-19 Symptom Tracker	NCT04331509		clinicaltrials.gov
NCT04331795 - Tocilizumab in Non-critical COVID Pneumonitis	NCT04331795		clinicaltrials.gov
NCT04331886 - Observational	NCT04331886		clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course	
Study of Coronavirus Disease 2019		
NCT04331899 - Peginterferon Lambda-1a in Outpatient Mild COVID	NCT04331899	clinicaltrials.gov
NCT04332081 - Hyperbaric Oxygen for COVID-19 Patients	NCT04332081	clinicaltrials.gov
NCT04332107 - Azithromycin for Treatment in Outpatients	NCT04332107	clinicaltrials.gov
NCT04332991 - Outcomes Related to Hydroxychloroquine	NCT04332991	clinicaltrials.gov
NCT04333225 - Hydroxychloroquine in Prevention in Workers	NCT04333225	clinicaltrials.gov
NCT04333654 - Hydroxychloroquine in Outpatient Adults With COVID	NCT04333654	clinicaltrials.gov
NCT04333732 - Chloroquine Repurposing to healthWorkers	NCT04333732	clinicaltrials.gov
NCT04333953 - COVID-19 in Patients With HIV	NCT04333953	clinicaltrials.gov
NCT04334382 - Hydroxychloroquine vs. Azithromycin (in Utah)	NCT04334382	clinicaltrials.gov
NCT04334460 - BLD-2660 in Hospitalized Subjects	NCT04334460	clinicaltrials.gov
NCT04334512 - Quintuple Therapy to Treat COVID	NCT04334512	clinicaltrials.gov
NCT04334954 - SARS-COV2 Pandemic Serosurvey and Blood Sampling	NCT04334954	clinicaltrials.gov
NCT04334967 - Hydroxychloroquine Compared to Standard of Care	NCT04334967	clinicaltrials.gov
NCT04335084 - Hydroxychloroquine, Vitamins, Zinc for Prevention	NCT04335084	clinicaltrials.gov
NCT04335123 - Study of Open Label Losartan	NCT04335123	clinicaltrials.gov
NCT04335552 - Hydroxychloroquine, Azithromycin for Severe COVID	NCT04335552	clinicaltrials.gov
NCT04335630 - CV Manifestations of COVID-19	NCT04335630	clinicaltrials.gov
NCT04336215 - Rutgers COVID-19 Cohort Study	NCT04336215	clinicaltrials.gov
NCT04336332 - Azithromycin and Hydroxychloroquine for COVID	NCT04336332	clinicaltrials.gov
NCT04336410 - INO-4800 for COVID in Healthy Volunteers	NCT04336410	clinicaltrials.gov
NCT04336774 - CAPTION AI to Minimize Risk of COVID Exposure	NCT04336774	clinicaltrials.gov
NCT04337762 - Beat COVID-19 - Observational Trial	NCT04337762	clinicaltrials.gov
NCT04338009 - Elimination or Prolongation of ACE-I and ARB	NCT04338009	clinicaltrials.gov
NCT04338074 - TXA and COVID19 in Outpatients	NCT04338074	clinicaltrials.gov
NCT04338126 - Tranexamic Acid and COVID in Inpatients	NCT04338126	clinicaltrials.gov
NCT04338347 - CAP-1002 in Severe COVID-19	NCT04338347	clinicaltrials.gov
NCT04338360 - Expanded Access to Convalescent Plasma Treatment	NCT04338360	clinicaltrials.gov
NCT04338828 - Nitric Oxide Inhalation Therapy in the ED	NCT04338828	clinicaltrials.gov
NCT04339387 - COVID-19 Risk Stratification	NCT04339387	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
NCT04339426 - Atovaquone and Azithromycin Combination for COVID	NCT04339426		clinicaltrials.gov
NCT04339634 - Risk With Drugs Repurposed for Treatment in Frail	NCT04339634		clinicaltrials.gov
NCT04339790 - Mental Health Impact of COVID Pandemic	NCT04339790		clinicaltrials.gov
NCT04339998 - Exam Findings in COVID With POCUS	NCT04339998		clinicaltrials.gov
NCT04340050 - COVID-19 Convalescent Plasma	NCT04340050		clinicaltrials.gov
NCT04340232 - Safety and Efficacy of Baricitinib	NCT04340232		clinicaltrials.gov
NCT04340479 - Use of Ultrasound as Part of a Trauma Evaluation	NCT04340479		clinicaltrials.gov
NCT04340557 - Angiotensin Receptor Blockers in ARDS-COVID	NCT04340557		clinicaltrials.gov
NCT04341012 - Breath Analysis Based Disease Biomarkers	NCT04341012		clinicaltrials.gov
NCT04341116 - TJ003234 (Anti-GM-CSF Antibody) in COVID	NCT04341116		clinicaltrials.gov
NCT04341441 - Will Hydroxychloroquine Impede or Prevent COVID-19	NCT04341441		clinicaltrials.gov
NCT04341675 - Sirolimus in Patients With COVID Pneumonia	NCT04341675		clinicaltrials.gov
NCT04341727 - Hydroxychloroquine, Azithromycin in Treatment	NCT04341727		clinicaltrials.gov
NCT04341935 - Effects of DPP4 Inhibition on COVID-19	NCT04341935		clinicaltrials.gov
NCT04342169 - Univ. Utah COVID-19 Hydrochloroquine	NCT04342169		clinicaltrials.gov
NCT04342195 - Convalescent Specimens for Antibodies	NCT04342195		clinicaltrials.gov
NCT04342637 - COVID-19 Endoscopy Survey	NCT04342637		clinicaltrials.gov
NCT04342663 - Fluvoxamine for Symptomatic Individuals With COVID	NCT04342663		clinicaltrials.gov
NCT04342728 - Using Ascorbic Acid and Zinc Supplementation	NCT04342728		clinicaltrials.gov
NCT04342806 - Healthcare Worker Exposure Response and Outcomes	NCT04342806		clinicaltrials.gov
NCT04342884 - COVID-19 Community Research Partnership	NCT04342884		clinicaltrials.gov
NCT04342897 - LY3127804 in COVID-19	NCT04342897		clinicaltrials.gov
NCT04343183 - Hyperbaric Oxygen Therapy (HBOT) as a Treatment	NCT04343183		clinicaltrials.gov
NCT04343261 - Convalescent Plasma in the Treatment of COVID 19	NCT04343261		clinicaltrials.gov
NCT04343651 - Leronlimab for Mild to Moderate COVID-19	NCT04343651		clinicaltrials.gov
NCT04343690 - COPING With COVID-19	NCT04343690		clinicaltrials.gov
NCT04343755 - Convalescent Plasma as Treatment	NCT04343755		clinicaltrials.gov
NCT04343898 - Treatment and Outcomes in Critically Ill Patients	NCT04343898		clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
NCT04343976 - Pegylated Interferon Lambda Treatment for COVID-19		NCT04343976	clinicaltrials.gov
NCT04343989 - IL-6-I Clazakizumab in Life-threatening COVID		NCT04343989	clinicaltrials.gov
NCT04344015 - COVID-19 Plasma Collection		NCT04344015	clinicaltrials.gov
NCT04344184 - Early Vitamin C for Treatment of Acute Lung Injury		NCT04344184	clinicaltrials.gov
NCT04344236 - Gargling/Nasal Rinse to Reduce Oro/Naso Viral Load		NCT04344236	clinicaltrials.gov
NCT04344444 - Treatment in Suspected or Confirmed COVID		NCT04344444	clinicaltrials.gov
NCT04344457 - Hydroxychloroquine, Indomethacin and Zithromax		NCT04344457	clinicaltrials.gov
NCT04344535 - Convalescent Plasma vs. Standard Plasma		NCT04344535	clinicaltrials.gov
NCT04344587 - smArtpHONE-based Trial Non-ICU Prone Positioning		NCT04344587	clinicaltrials.gov
NCT04344600 - Peginterferon Lambda for Prevention and Treatment		NCT04344600	clinicaltrials.gov
NCT04344977 - Collection of Anti-SARS-CoV-2 Immune Plasma		NCT04344977	clinicaltrials.gov
NCT04345601 - Stromal Cells for COVID Respiratory Failure		NCT04345601	clinicaltrials.gov
NCT04345614 - CM4620-Injectable Emulsion in COVID Pneumonia		NCT04345614	clinicaltrials.gov
NCT04345653 - Hydroxychloroquine Chemoprevention for High Risk		NCT04345653	clinicaltrials.gov
NCT04345692 - Hydroxychloroquine for the Treatment of COVID		NCT04345692	clinicaltrials.gov
NCT04346615 - Vazegepant in patients Requiring Supplemental O2		NCT04346615	clinicaltrials.gov
NCT04346628 - Favipiravir Compared to Standard Supportive Care		NCT04346628	clinicaltrials.gov
NCT04347226 - Anti-Interleukin -8 for Patients With COVID		NCT04347226	clinicaltrials.gov
NCT04347239 - Leronlimab for Severe or Critical COVID		NCT04347239	clinicaltrials.gov
NCT04347538 - Nasal Saline Irrigations on Viral Load		NCT04347538	clinicaltrials.gov
NCT04347954 - PVP-I Nasal Sprays and Nasopharyngeal Titers		NCT04347954	clinicaltrials.gov
NCT04347993 - Prospective "Universal" Observational Database		NCT04347993	clinicaltrials.gov
NCT04348240 - Transmissibility and Viral Load in Oral Secretions		NCT04348240	clinicaltrials.gov
NCT04348370 - BCG Vaccine for Health Care Workers		NCT04348370	clinicaltrials.gov
NCT04348435 - Hope Biosciences Allogeneic Mesenchymal Stem Cell		NCT04348435	clinicaltrials.gov
NCT04348864 - Antibody Self-testing Using Virtual Point-of-care		NCT04348864	clinicaltrials.gov
NCT04349098 - Oral Selinexor in Severe COVID		NCT04349098	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
NCT04349202 - Beaumont Large-scale Automated Serologic Testing		NCT04349202	clinicaltrials.gov
NCT04349371 - Saved From COVID-19		NCT04349371	clinicaltrials.gov
NCT04349410 - The Fleming Directed CoVid Protocol		NCT04349410	clinicaltrials.gov
NCT04349631 - Autologous Mesenchymal Stem Cell Therapy		NCT04349631	clinicaltrials.gov
NCT04350073 - Longitudinal Energy Expenditure in COVID		NCT04350073	clinicaltrials.gov
NCT04350450 - Hydroxychloroquine Treatment (Montefiore)		NCT04350450	clinicaltrials.gov
NCT04350476 - COVID-19 Remote Monitoring		NCT04350476	clinicaltrials.gov
NCT04350593 - Dapagliflozin in Respiratory Failure		NCT04350593	clinicaltrials.gov
NCT04351152 - Lenzilumab in Hospitalized COVID Pneumonia		NCT04351152	clinicaltrials.gov
NCT04351243 - Gimsilumab in Lung Injury or ARDS due to COVID		NCT04351243	clinicaltrials.gov
NCT04351620 - High-dose Hydroxychloroquine for Mild COVID		NCT04351620	clinicaltrials.gov
NCT04351880 - A Trial of Medically Tailored Meals Post Discharge		NCT04351880	clinicaltrials.gov
NCT04352634 - Covid-19 HEalth caRe wOrkErS		NCT04352634	clinicaltrials.gov
NCT04352764 - COVID ANTIBODY BASED TESTS in Healthcare Settings		NCT04352764	clinicaltrials.gov
NCT04352946 - HEalth Care Worker pROphylaxis Against COVID		NCT04352946	clinicaltrials.gov
NCT04353037 - PATCH 2&3:Prevention COVID With Hydroxychloroquine		NCT04353037	clinicaltrials.gov
NCT04353206 - Convalescent Plasma in ICU Respiratory Failure		NCT04353206	clinicaltrials.gov
NCT04353271 - Trial of Hydroxychloroquine In Covid-19 Kinetics		NCT04353271	clinicaltrials.gov
NCT04353401 - WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS		NCT04353401	clinicaltrials.gov
NCT04354155 - Anticoagulation in Children		NCT04354155	clinicaltrials.gov
NCT04354428 - Treatment for COVID in High-Risk Adult Outpatients		NCT04354428	clinicaltrials.gov
NCT04354701 - COVID-19 and Cancer Consortium Registry		NCT04354701	clinicaltrials.gov
NCT04354714 - Ruxolitinib to Combat COVID-19		NCT04354714	clinicaltrials.gov
NCT04354870 - COVID-19 PrEP HCW HCQ Study		NCT04354870	clinicaltrials.gov
NCT04355143 - Colchicine to Reduce Myocardial Injury		NCT04355143	clinicaltrials.gov
NCT04355728 - Use of UC-MSCs for COVID-19		NCT04355728	clinicaltrials.gov
NCT04355767 - Convalescent Plasma in ER		NCT04355767	clinicaltrials.gov
NCT04355897 - CoVID-19 Plasma in Treatment of COVID-19 Patients		NCT04355897	clinicaltrials.gov
NCT04356443 - Non-Invasive Monitoring of Respiratory		NCT04356443	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course
Function	
NCT04356690 - Etoposide in COVID-19	NCT04356690 clinicaltrials.gov
NCT04356937 - Efficacy of Tocilizumab on COVID-19	NCT04356937 clinicaltrials.gov
NCT04357041 - Dietary Intake, Physical Activity, Well-being	NCT04357041 clinicaltrials.gov
NCT04357574 - Radiotherapy During Changes in Response to COVID	NCT04357574 clinicaltrials.gov
NCT04357782 - IV Vitamin C in COVID-19 and Decreased Oxygenation	NCT04357782 clinicaltrials.gov
NCT04358003 - Plasma Adsorption in Confirmed COVID	NCT04358003 clinicaltrials.gov
NCT04358029 - Cardiac Arrhythmias In COVID	NCT04358029 clinicaltrials.gov
NCT04358068 - Efficacy of Hydroxychloroquine and Azithromycin	NCT04358068 clinicaltrials.gov
NCT04358211 - Convalescent Plasma to Treat Pulm. Complications	NCT04358211 clinicaltrials.gov
NCT04358510 - COVID-19 Mortality Prediction Model	NCT04358510 clinicaltrials.gov
NCT04358536 - COVID-19 in Posteroanterior Chest X-rays	NCT04358536 clinicaltrials.gov
NCT04358549 - Favipiravir in Hospitalized patients With COVID	NCT04358549 clinicaltrials.gov
NCT04359277 - Anticoagulation Strategies in COVID-19	NCT04359277 clinicaltrials.gov
NCT04359329 - Estrogen Patch for COVID-19 Symptoms	NCT04359329 clinicaltrials.gov
NCT04359602 - COVID-19 Recovered Volunteer Research Registry	NCT04359602 clinicaltrials.gov
NCT04359797 - COVID-19 Patient Positioning Pragmatic Trial	NCT04359797 clinicaltrials.gov
NCT04359810 - Plasma Therapy of COVID in Critically Ill Patients	NCT04359810 clinicaltrials.gov
NCT04359836 - the Role of Gut Flora in COVID Infection	NCT04359836 clinicaltrials.gov
NCT04359901 - Sarilumab for Moderate COVID	NCT04359901 clinicaltrials.gov
NCT04360278 - Plasma Collection From Convalescent or Immunized	NCT04360278 clinicaltrials.gov
NCT04360538 - Long Term Outcomes of Patients With COVID-19	NCT04360538 clinicaltrials.gov
NCT04360551 - Telmisartan for Pulmonary and CV Complications	NCT04360551 clinicaltrials.gov
NCT04360850 - Telehealth by Mental Health Care Professionals	NCT04360850 clinicaltrials.gov
NCT04360954 - Evaluation of Antibody Tests for COVID-19	NCT04360954 clinicaltrials.gov
NCT04361123 - Atrium COVID Syndromic and Serologic Surveillance	NCT04361123 clinicaltrials.gov
NCT04361214 - Leflunomide in Mild COVID-19 Patients	NCT04361214 clinicaltrials.gov
NCT04361552 - Tocilizumab for Cytokine Release Syndrome in COVID	NCT04361552 clinicaltrials.gov
NCT04362150 - Long-term	NCT04362150 clinicaltrials.gov



Section: Clinical Trial	Parent: Hospital Course		
Impact of Infection With COVID			
NCT04362176 - Passive Immunity Trial of Nashville II for COVID		NCT04362176	clinicaltrials.gov
NCT04362189 - Allogeneic HB-adMSCs for Treatment		NCT04362189	clinicaltrials.gov
NCT04362813 - Canakinumab for CRS in COVID-induced Pneumonia		NCT04362813	clinicaltrials.gov
NCT04362865 - B- and T-cell Response in Acute and Resolved COVID		NCT04362865	clinicaltrials.gov
NCT04362995 - St. Jude Tracking of Viral and Host Factors		NCT04362995	clinicaltrials.gov
NCT04363203 - Remote Equitable Access to COVID-19 Healthcare		NCT04363203	clinicaltrials.gov
NCT04363268 - Master Digital Surveillance Protocol for COVID		NCT04363268	clinicaltrials.gov
NCT04363346 - FT516 for the Treatment of Patients With Hypoxia		NCT04363346	clinicaltrials.gov
NCT04363437 - Colchicine in Moderate-severe Patient Before ARDS		NCT04363437	clinicaltrials.gov
NCT04363450 - Hydroxychloroquine as Prophylaxis		NCT04363450	clinicaltrials.gov
NCT04363866 - Hydroxychloroquine in COVID-19		NCT04363866	clinicaltrials.gov
NCT04364737 - Convalescent Plasma to Limit Complications		NCT04364737	clinicaltrials.gov
NCT04364802 - Povidone-Iodine Intranasal Prophylaxis		NCT04364802	clinicaltrials.gov
NCT04365127 - Progesterone for Treatment of COVID-19		NCT04365127	clinicaltrials.gov
NCT04365153 - Canakinumab for Cardiac and Respiratory Function		NCT04365153	clinicaltrials.gov
NCT04365257 - Prazosin to Prevent COVID-19		NCT04365257	clinicaltrials.gov
NCT04365699 - CV Effects of COVID-19		NCT04365699	clinicaltrials.gov
NCT04365985 - Immunomodulation Using Naltrexone and Ketamine		NCT04365985	clinicaltrials.gov
NCT04366791 - Radiation Eliminates Storming Cytokines and Edema		NCT04366791	clinicaltrials.gov
NCT04366830 - Mesenchymal Stromal Cells for ARDS Due to COVID		NCT04366830	clinicaltrials.gov
NCT04366986 - COVID Exposure in Pregnancy		NCT04366986	clinicaltrials.gov
NCT04367077 - MultiStem Administration for COVID Induced ARDS		NCT04367077	clinicaltrials.gov
NCT04367740 - Determine Asymptomatic Who Have Antibodies		NCT04367740	clinicaltrials.gov
NCT04367831 - Anticoags for Venous or Arterial Thromboembolism		NCT04367831	clinicaltrials.gov
NCT04367857 - COVID-19 Seroprevalence Among Healthcare Workers		NCT04367857	clinicaltrials.gov
NCT04368065 - Factors That May Impact COVID Occurrence		NCT04368065	clinicaltrials.gov
NCT04368234 - Duke COVID-19 Shared Data and Specimen		NCT04368234	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course
Repository	
NCT04368260 - Validation of Molded Flocked Nasopharyngeal Swabs	NCT04368260 clinicaltrials.gov
NCT04368728 - RNA Vaccine Against COVID in Healthy Adults	NCT04368728 clinicaltrials.gov
NCT04369599 - Trans Thoracic Manipulation Ventilation/Perfusion	NCT04369599 clinicaltrials.gov
NCT04369742 - Treating COVID-19 With Hydroxychloroquine	NCT04369742 clinicaltrials.gov
NCT04369989 - COVID-19 Treatment Efficacy	NCT04369989 clinicaltrials.gov
NCT04370262 - Adaptive Trials Using Hydroxychloroquine	NCT04370262 clinicaltrials.gov
NCT04370782 - Hydroxychloroquine and Zinc in Outpatient Setting	NCT04370782 clinicaltrials.gov
NCT04370821 - Healthcare, First Responder and Service Workers	NCT04370821 clinicaltrials.gov
NCT04370938 - Provider Burnout During COVID-19	NCT04370938 clinicaltrials.gov
NCT04371315 - Acute Infection With COVID In Children	NCT04371315 clinicaltrials.gov
NCT04371393 - MSCs in COVID-19 ARDS	NCT04371393 clinicaltrials.gov
NCT04371432 - Genetics COVID Susceptibility and Manifestations	NCT04371432 clinicaltrials.gov
NCT04371640 - Sirolimus in COVID-19 Phase 1	NCT04371640 clinicaltrials.gov
NCT04372368 - Convalescent Plasma for the Treatment	NCT04372368 clinicaltrials.gov
NCT04372472 - SQuISH-COVID: A Pilot Study	NCT04372472 clinicaltrials.gov
NCT04372602 - Duvelisib to Combat COVID-19	NCT04372602 clinicaltrials.gov
NCT04372628 - Early Therapies During Outpatient Window	NCT04372628 clinicaltrials.gov
NCT04373044 - Antiviral Therapy and Baricitinib for Severe COVID	NCT04373044 clinicaltrials.gov
NCT04373135 - Community Consideration, Opinion, Value, Impact	NCT04373135 clinicaltrials.gov
NCT04373148 - Understanding Immunity to SARS-CoV-2	NCT04373148 clinicaltrials.gov
NCT04373161 - Home Pulse Oximeter Use	NCT04373161 clinicaltrials.gov
NCT04374019 - Novel Agents for Treatment of High-risk Patients	NCT04374019 clinicaltrials.gov
NCT04374071 - Early Short Course Corticosteroids in COVID-19	NCT04374071 clinicaltrials.gov
NCT04374279 - Recovery With Ivermectin or Endocrine Therapy	NCT04374279 clinicaltrials.gov
NCT04374370 - Convalescent Plasma Expanded Access Protocol	NCT04374370 clinicaltrials.gov
NCT04374461 - N-acetylcysteine in COVID	NCT04374461 clinicaltrials.gov
NCT04374552 - Asymptomatic COVID-19 Trial	NCT04374552 clinicaltrials.gov
NCT04374565 - Convalescent Plasma for Patients With	NCT04374565 clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
Pneumonia			
NCT04374786 - Mobile App in House Staff Health and Well-being		NCT04374786	clinicaltrials.gov
NCT04375761 - Human Epidemiology and Response to COVID		NCT04375761	clinicaltrials.gov
NCT04376034 - Convalescent Plasma Collection and Treatment		NCT04376034	clinicaltrials.gov
NCT04376515 - Harnessing Online Peer Education Support		NCT04376515	clinicaltrials.gov
NCT04376593 - PET/CT Imaging in COVID-19		NCT04376593	clinicaltrials.gov
NCT04376710 - Surgical Telemedicine in the Pandemic Era		NCT04376710	clinicaltrials.gov
NCT04377100 - Impact on Anxiety and Predictors of Responses		NCT04377100	clinicaltrials.gov
NCT04377308 - Fluoxetine to Reduce Intubation and Death		NCT04377308	clinicaltrials.gov
NCT04377412 - Risk for Anxiety and Depression in Pregnant Women		NCT04377412	clinicaltrials.gov
NCT04377581 - Health Messaging Efficacy and Impact on Behavior		NCT04377581	clinicaltrials.gov
NCT04377620 - Ruxolitinib in COVID-ARDS with Mechanical Vent.		NCT04377620	clinicaltrials.gov
NCT04377659 - Tocilizumab for Prevention of Respiratory Failure		NCT04377659	clinicaltrials.gov
NCT04378595 - Pediatric Food Insecurity (Austin)		NCT04378595	clinicaltrials.gov
NCT04378777 - Immunophenotyping Assessment in a COVID Cohort		NCT04378777	clinicaltrials.gov
NCT04378803 - Mindfulness Training for Seniors		NCT04378803	clinicaltrials.gov
NCT04379089 - Neurologic Manifestations of COVID 19 in Children		NCT04379089	clinicaltrials.gov
NCT04379284 - Risks of COVID19 in the Pregnant Population		NCT04379284	clinicaltrials.gov
NCT04379492 - Hydroxychloroquine Compared to Placebo		NCT04379492	clinicaltrials.gov
NCT04379518 - Rintatolimod and IFN Alpha-2b for COVID		NCT04379518	clinicaltrials.gov
NCT04379544 - Value of Point of Care Cardiac and Lung Ultrasound		NCT04379544	clinicaltrials.gov
NCT04379661 - Online Support Groups for MS		NCT04379661	clinicaltrials.gov
NCT04380688 - Acalabrutinib With Best Supportive Care		NCT04380688	clinicaltrials.gov
NCT04380870 - Chinese Herbal Medicine Telehealth Care for COVID		NCT04380870	clinicaltrials.gov
NCT04380948 - NT-I7 to Enhance Immune Clearance of COVID-19		NCT04380948	clinicaltrials.gov
NCT04380961 - Sirukumab in Confirmed Severe or Critical COVID		NCT04380961	clinicaltrials.gov
NCT04381013 - Emergency Ventilator Splitting Between Patients		NCT04381013	clinicaltrials.gov
NCT04381052 - Clazakizumab		NCT04381052	clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course
in Life-threatening COVID Infection	
NCT04381988 - Hydroxychloroquine in Radiotherapy	NCT04381988 clinicaltrials.gov
NCT04382391 - Vagus Nerve Stimulation in Respiratory Symptoms	NCT04382391 clinicaltrials.gov
NCT04382586 - Pulmonary Distress Treatment With Zanubrutinib	NCT04382586 clinicaltrials.gov
NCT04382625 - Hydroxychloroquine in COVID Pneumonia Trial	NCT04382625 clinicaltrials.gov
NCT04383444 - Surveillance Following Exposure	NCT04383444 clinicaltrials.gov
NCT04383587 - Antibody Seroprevalence in Undiagnosed Workers	NCT04383587 clinicaltrials.gov
NCT04384055 - Predicting Outcomes for Covid-19 Using Sonography	NCT04384055 clinicaltrials.gov
NCT04384445 - Organiceff Flow for Patients With COVID-19	NCT04384445 clinicaltrials.gov
NCT04385147 - Advanced Endoscopy During COVID-19	NCT04385147 clinicaltrials.gov
NCT04385199 - Convalescent Plasma for Patients With COVID-19	NCT04385199 clinicaltrials.gov
NCT04385251 - International COVID Infection Observational Study	NCT04385251 clinicaltrials.gov
NCT02735707 - Multifactorial Adaptive Platform for Pneumonia	NCT02735707 clinicaltrials.gov
NCT04193878 - ARrest RESpiraTory Failure From PNEUMONIA	NCT04193878 clinicaltrials.gov
NCT04334148 - HERO-Hydroxychloroquine	NCT04334148 clinicaltrials.gov
NCT04342689 - The Role of Resistant Starch in COVID-19 Infection	NCT04342689 clinicaltrials.gov
NCT04343248 - Nitazoxanide for Post-Exposure in Long-Term Care	NCT04343248 clinicaltrials.gov
NCT04348656 - CONvalescent Plasma for Hospitalized Adults	NCT04348656 clinicaltrials.gov
NCT04358081 - Hydroxychloroquine Mono and With Azithromycin	NCT04358081 clinicaltrials.gov
NCT04359680 - Nitazoxanide for Post Exposure Prophylaxis	NCT04359680 clinicaltrials.gov
NCT04360824 - Covid-19 Associated Coagulopathy	NCT04360824 clinicaltrials.gov
NCT04361253 - SARS-CoV-2 Antibody-containing Plasma thErapy	NCT04361253 clinicaltrials.gov
NCT04362137 - Ruxolitinib in COVID Associated Cytokine Storm	NCT04362137 clinicaltrials.gov
NCT04369469 - IV Ravulizumab in COVID Severe Pneumonia	NCT04369469 clinicaltrials.gov
NCT04372017 - Hydroxychloroquine as Post-Exposure Prophylaxis	NCT04372017 clinicaltrials.gov
NCT04372186 - Tocilizumab in COVID-19 Pneumonia	NCT04372186 clinicaltrials.gov
NCT04372589 - Antithrombotic to Ameliorate Complications	NCT04372589 clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course		
NCT04377711 - Ciclesonide in the Non-hospitalized COVID	NCT04377711		clinicaltrials.gov
NCT04389840 - Dociparstat for High Risk Respiratory Failure	NCT04389840		clinicaltrials.gov
NCT04394416 - Imatinib for Hospitalized Adults	NCT04394416		clinicaltrials.gov
NCT04397510 - Nebulized Heparin for COVID Induced Lung Injury	NCT04397510		clinicaltrials.gov
NCT04400058 - Octagam 10 Percent in COVID Patients With Severe Disease	NCT04400058		clinicaltrials.gov
NCT04401293 - Full Dose Heparin Vs Intermediate Dose Heparin	NCT04401293		clinicaltrials.gov
NCT04401579 - Adaptive COVID-19 Treatment Trial 2	NCT04401579		clinicaltrials.gov
NCT04402970 - Dornase Alfa for ARDS in Patients With SARS-CoV-2	NCT04402970		clinicaltrials.gov
NCT04404361 - PRE-VENT in COVID With or Without Cancer	NCT04404361		clinicaltrials.gov
NCT04406389 - Anticoagulation in Critically Ill Patients	NCT04406389		clinicaltrials.gov
NCT04409262 - Remdesivir Plus Tocilizumab	NCT04409262		clinicaltrials.gov
NCT04409327 - RTB101 Severity in Older Adults in Nursing Homes	NCT04409327		clinicaltrials.gov
NCT04411667 - IVIG Compared to Standard of Care	NCT04411667		clinicaltrials.gov
NCT04412772 - Tocilizumab - Tx of Severe COVID	NCT04412772		clinicaltrials.gov
NCT04418518 - CONvalescent Plasma for Adults With Acute COVID	NCT04418518		clinicaltrials.gov
NCT04421027 - Baricitinib - LY3009104 - in Participants With COVID	NCT04421027		clinicaltrials.gov
NCT04421508 - Pulsed Inhaled Nitric Oxide vs Placebo	NCT04421508		clinicaltrials.gov
NCT04421664 - Preemptive Therapy for SARS-Coronavirus-2	NCT04421664		clinicaltrials.gov
NCT04429867 - Hydroxychloroquine Impact on Progression	NCT04429867		clinicaltrials.gov
NCT04431453 - Remdesivir in COVID-19	NCT04431453		clinicaltrials.gov
NCT04433949 - Best Supportive Care With Lung Radiation Therapy	NCT04433949		clinicaltrials.gov
NCT04439071 - PTC299 in Hospitalized Participants	NCT04439071		clinicaltrials.gov
NCT04441996 - Therapeutic Plasma Exchange	NCT04441996		clinicaltrials.gov
NCT04447469 - Mavrilimumab in Hospitalized Severe COVID-19	NCT04447469		clinicaltrials.gov
NCT04452318 - Anti-Spike SARS CoV-2 Monoclonal Antibodies	NCT04452318		clinicaltrials.gov
NCT04452474 - Olokizumab vs Placebo	NCT04452474		clinicaltrials.gov
NCT04452565 - NA-831 Atazanavir and Dexamethasone	NCT04452565		clinicaltrials.gov
NCT04470427 - mRNA-1273 Vaccine in Adults	NCT04470427		clinicaltrials.gov
NCT04472611 - Colchicine/Statins for	NCT04472611		clinicaltrials.gov

Section: Clinical Trial	Parent: Hospital Course
Prevention	
NCT04473274 - GiltazOne Treatment for Coronavirus HypoxiA	NCT04473274 clinicaltrials.gov
NCT04482673 - Vitamin D in Prevention and Mitigation	NCT04482673 clinicaltrials.gov

**Section: Administration**
**Parent: Root**

<b>Element:</b> 1000	Participant ID
<p><b>Coding Instruction:</b> Indicate the participant ID of the submitting facility.</p> <p><b>Target Value:</b> N/A</p> <p><b>Supporting Definition: Participant ID</b></p> <p>Participant ID is a unique number assigned to each database participant by NCDR. A database participant is defined as one entity that signs a Participation Agreement with the NCDR, submits one data submission file to the harvest, and receives one report on their data.</p> <p>Each participant's data if submitted to harvest must be in one data submission file for a quarter. If one participant keeps their data in more than one file (e.g. at two sites), then the data must be combined into a single data submission to the system to file for the harvest. If two or more participants share a single purchased software, and enter cases into one database, then the data must be exported into different data submission files, one for each participant ID.</p> <p><b>Source:</b> NCDR</p>	
<b>Element:</b> 1010	Participant Name
<p><b>Coding Instruction:</b> Indicate the full name of the facility where the procedure was performed.</p> <p>Note(s): Values should be full, official hospital names with no abbreviations or variations in spelling.</p> <p><b>Target Value:</b> N/A</p> <p><b>Supporting Definition: Participant Name</b></p> <p>Indicate the full name of the facility where the procedure was performed. Values should be full, official hospital names with no abbreviations or variations in spelling.</p> <p><b>Source:</b> NCDR</p>	
<b>Element:</b> 1020	Time Frame of Data Submission
<p><b>Coding Instruction:</b> Indicate the time frame of data included in the data submission. Format: YYYYQQ. e.g.,2016Q1</p> <p><b>Target Value:</b> N/A</p>	
<b>Element:</b> 1040	Transmission Number
<p><b>Coding Instruction:</b> This is a unique number created, and automatically inserted by the software into export file. It identifies the number of times the software has created a data submission file. The transmission number should be incremented by one every time the data submission files are exported. The transmission number should never be repeated.</p> <p><b>Target Value:</b> N/A</p>	
<b>Element:</b> 1050	Vendor Identifier
<p><b>Coding Instruction:</b> Vendor identification (agreed upon by mutual selection between the vendor and the NCDR) to identify software vendor. This is entered into the schema automatically by vendor software. Vendors must use consistent name identification across sites. Changes to vendor name identification must be approved by the NCDR.</p> <p><b>Target Value:</b> N/A</p>	
<b>Element:</b> 1060	Vendor Software Version
<p><b>Coding Instruction:</b> Vendor's software product name and version number identifying the software which created this record (assigned by vendor). Vendor controls the value in this field. This is entered into the schema automatically by vendor software.</p> <p><b>Target Value:</b> N/A</p>	
<b>Element:</b> 1070	Registry Identifier
<p><b>Coding Instruction:</b> The NCDR registry identifier describes the data registry to which these records apply. It is implemented in the software at the time the data is collected and records are created. This is entered into the schema automatically by software.</p> <p><b>Target Value:</b> N/A</p>	
<b>Element:</b> 1071	Registry Schema Version
<p><b>Coding Instruction:</b> Schema version describes the version number of the Registry Transmission Document (RTD) schema to which each record conforms. It is an attribute that includes a constant value indicating the version of schema file. This is entered into the schema automatically by software.</p> <p><b>Target Value:</b> N/A</p>	

**Section: Administration** **Parent: Root**

**Element:** 1085 Submission Type

**Coding Instruction:** Indicate if the data contained in the harvest/data file contains either standard patient episode of care records (arrival date to discharge only) or if it contains patient follow-up records.

A transmission file with all episode of care records (from Arrival to Discharge only) is considered a 'Base Registry Record'.

A file with patient follow-up records (any follow-up assessments performed during the quarter selected) is considered a 'Follow-Up Record'.

**Note(s):**

Selecting 'Follow-Up Records Only' will transmit all patient records with Follow-up Assessment Dates (Element Ref# 11000) contained in the selected timeframe, regardless of the procedure or discharge date. For example, if a patient has a procedure on 3/30/2017, is discharged on 3/31/2017, and has a follow-up assessment on 5/6/2017, the patient's episode of care data will be transmitted in the 2017Q1 Base Registry Record file, but the Follow-up data will be transmitted in the 2017Q2 Follow-Up File.

**Target Value:** N/A

**Submission Type**

Selection	Definition	Source	Code	Code System
Episode of Care Records Only			1000142424	ACC NCDR